#China #Beijing #NSCLC #Cancer Hospital #LK101

LK101: Pioneering Cancer Treatment in Advanced Stages

On October 24, 2026, a groundbreaking report was presented at the ESMO Congress 2026 in Madrid, Spain. The team led by Professors Jie Wang, Zhijie Wang, and Jianchun Duan from the Cancer Hospital of the Chinese Academy of Medical Sciences unveiled the results of their Phase 1b/2a study, demonstrating a remarkable 95.2% disease control rate with the combination therapy of LK101 and tislelizumab for patients suffering from advanced non-small cell lung cancer (NSCLC).

Overview of the Study

The focus of the study centers on LK101, a personalized dendritic cell vaccine tailored to the unique genetic markers of a patient's tumor. This innovative therapy, alongside tislelizumab, aims to maintain disease control in patients who have already undergone platinum-doublet chemotherapy and anti-PD-1 antibody treatment. The participating patients did not show any actionable driver mutations and had a PD-L1 TPS of 1% or higher.

Initiated by Professor Jie Wang's team, the study was independently conducted, employing a well-structured methodology (NCT05886439) using LK101 sourced from Likang Life Sciences. This pioneering therapy utilizes autologous dendritic cells transfected with messenger RNA encoding up to 30 specific tumor neoantigens, thus spotlighting a tailored approach to immunotherapy.

Key Findings and Results

As of March 31, 2026, a total of 26 patients were enrolled in the study, with 25 of them receiving LK101. Out of 21 patients who were evaluable for efficacy, 4 demonstrated confirmed partial responses to the treatment. The overall response rate (ORR) was recorded at 19.0%, showcasing the preliminary effectiveness of this novel therapy. The findings indicated that not only did patients achieve significant disease control, but some even experienced further tumor shrinkage during the maintenance therapy phase.

With a median follow-up period of 9.5 months, the median progression-free survival (PFS) was not reached, while PFS rates at 9 months sat at an impressive 85.4%, and 70.4% at 12 months. The ELISpot analysis demonstrated an enhancement in neoantigen-specific T-cell responses, further solidifying LK101's potential to induce an immune response correlated with clinical activity. Notably, partial responders exhibited higher responses in post-priming ELISpot assessments.

Safety Profile and Future Directions

Safety assessments highlighted that most adverse events related to LK101 were classified as Grade 1–2, with the overall safety profile deemed manageable by investigators. Commentary from the session discussant noted the impressive PFS rates and favorable results from ELISpot findings, although further validation of clinical benefit is warranted.

Following the success of this trial, a multicenter, randomized controlled Phase 2 trial has been initiated to further evaluate the efficacy and safety profiles of LK101 in conjunction with tislelizumab as first-line maintenance therapy in advanced NSCLC.

Conclusion

Likang Life Sciences, the company behind LK101, is a leader in the realm of AI-powered precision cancer immunotherapy. By leveraging cutting-edge technology, bioinformatics, and genomics, they continue to develop personalized cancer treatments aimed at enhancing the efficacy of therapies based on individual tumor characteristics. With the promising results emerging from this recent study, LK101 may soon become a pivotal option in the treatment landscape for patients with advanced NSCLC, paving the way for the next generation of tailored cancer therapies.

For further information about Likang Life Sciences, visit their website at www.likanglife.com.